Skip to main content
. 2020 Feb;9(1):90–102. doi: 10.21037/tlcr.2019.12.28

Figure 4.

Figure 4

Patients with lymphoma in remission compared with those with active lymphoma presented significant better survival [64 (range, 59–85) vs. 37 (range, 13–75) months; HR: 2.4; P=0.02; Part A], but lung cancer specific survival showed no significant difference [27 (range, 18–85) vs. 19 (range, 13–37) months; HR: 0.3; P=0.17; Part B].